IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: I. Luttichuys who wrote (29)	9/16/1996 4:53:00 PM
From: Rick Costantino	of 1762

I agree with your assessment, so far all data I have seen indicate >=50% response rate with minimal side effects. The data on relapse so far looks very good. However, collection of these data are ongoing and may take a long time to gather. Of course, this depends on the endpoint you are looking for, 1, 2 etc... years. Anyway, collecting these data are not going to affect the approval of anti-CD-20 (C2B8). Perhaps this latest move in the price is an indication of positive news on C2B8 or the arthritis drug? Or just speculation? Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next